-transparent.png){kind=logo}
A case history is presented of a patient who developed a severe phenytoin intoxication on a "therapeutic" dose of 300 mg/day. This phenomenon could be ascribed to a poor oxidative metabolizing capacity of this patient for phenytoin, as demonstrated by a low para-hydroxyphenyl-phenylhydantoin to phenytoin ratio in the urine. To characterize the specificity of this metabolic defect, debrisoquine and antipyrine oxidation were also studied. Contrary to expectations, this patient was shown to be an extensive debrisoquine metabolizer; the antipyrine clearance was even higher than normal. These findings suggest that phenytoin para-hydroxylation is regulated by an oxidative enzyme complex different from those which oxidize debrisoquine and antipyrine.
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
January 2015,
American journal of therapeutics,
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
May 1990,
Journal of the neurological sciences,
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
January 1990,
DICP : the annals of pharmacotherapy,
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
April 2007,
Nederlands tijdschrift voor geneeskunde,
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
January 2007,
Nederlands tijdschrift voor geneeskunde,
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
July 1975,
Clinical pharmacology and therapeutics,
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
November 1981,
The Western journal of medicine,
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
October 1985,
Harefuah,
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
January 2004,
Neurology,
F A de Wolff, and
P Vermeij, and
M D Ferrari, and
O J Buruma, and
D D Breimer
January 2004,
Neurology,
